ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 49,600 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 49,600 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $11.21, for a total transaction of $556,016.00. Following the completion of the sale, the director now owns 210,346 shares in the company, valued at approximately $2,357,978.66. This trade represents a 19.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Laura Shawver also recently made the following trade(s):

• On Monday, February 3rd, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $12.31, for a total transaction of $615,500.00.
• On Monday, January 6th, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00.

ARS Pharmaceuticals Trading Up 0.6 %

Shares of SPRY stock opened at $10.85 on Friday. ARS Pharmaceuticals, Inc. has a 12 month low of $7.55 and a 12 month high of $18.51. The firm has a market capitalization of $1.05 billion, a PE ratio of -21.27 and a beta of 1.03. The firm has a fifty day simple moving average of $11.87 and a two-hundred day simple moving average of $13.16.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on SPRY shares. Raymond James increased their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 14th. Leerink Partners raised their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Oppenheimer started coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price objective for the company. Scotiabank began coverage on shares of ARS Pharmaceuticals in a research report on Friday. They issued a “sector outperform” rating and a $30.00 price objective for the company. Finally, William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, ARS Pharmaceuticals has an average rating of “Buy” and a consensus price target of $29.00.

Institutional Investors Weigh In On ARS Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP grew its position in ARS Pharmaceuticals by 0.6% during the fourth quarter. Wellington Management Group LLP now owns 163,252 shares of the company’s stock valued at $1,722,000 after acquiring an additional 917 shares during the last quarter. Rhumbline Advisers lifted its stake in ARS Pharmaceuticals by 2.9% in the fourth quarter. Rhumbline Advisers now owns 65,163 shares of the company’s stock worth $687,000 after acquiring an additional 1,824 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in ARS Pharmaceuticals by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $217,000 after acquiring an additional 1,962 shares during the period. Mariner LLC lifted its position in ARS Pharmaceuticals by 5.8% during the fourth quarter. Mariner LLC now owns 35,908 shares of the company’s stock valued at $379,000 after buying an additional 1,972 shares during the period. Finally, LPL Financial LLC lifted its position in ARS Pharmaceuticals by 11.4% during the fourth quarter. LPL Financial LLC now owns 21,408 shares of the company’s stock valued at $226,000 after buying an additional 2,190 shares during the period. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.